» Articles » PMID: 33754418

Anti-SARS-CoV-2 Vaccination Strategy for Pregnant Women in Japan

Overview
Date 2021 Mar 23
PMID 33754418
Citations 15
Authors
Affiliations
Soon will be listed here.
Abstract

The current COVID-19 pandemic is a global concern. The recent introduction of vaccines has provided a reason for hope, but new problems, such as vaccine hesitancy, have arisen. One of the most important of these issues is the safety of vaccines for pregnant women. In this article, we collected worldwide indications for vaccination, including women who are pregnant or who wish to become pregnant, and reports of adverse reactions to COVID-19 vaccination. The Japan Society of Obstetrics and Gynecology and the Japanese Society of Infectious Diseases in Obstetrics and Gynecology have published recommendations for the vaccination of pregnant women with a COVID-19 vaccine. The guidelines are as follows: (1) pregnant women should not be excluded from vaccination; (2) informed consent should be obtained before vaccination; (3) healthcare workers and pregnant women with complications such as diabetes, hypertension, and obesity should be vaccinated preferentially; (4) vaccination should be avoided until 12 weeks of gestation during organogenesis; (5) spouse and family members should be vaccinated actively; and (6) nursing mothers are not particularly affected. This policy has been adopted in government guidelines. Additional efforts should be made to protect pregnant women from infection and severe illness with COVID-19 by eliminating vaccine hesitancy.

Citing Articles

COVID19 Vaccination Considerations for Pregnant Women: A Systematic Review.

Ghafari Z, Khameneh A, Vahedi L Iran J Nurs Midwifery Res. 2024; 29(4):389-396.

PMID: 39205836 PMC: 11349169. DOI: 10.4103/ijnmr.ijnmr_146_22.


Safety of COVID-19 Vaccination in Pregnancy: A Systematic Review.

Gerede A, Daskalakis G, Mikos T, Chatzakis C, Vavoulidis E, Eleftheriades M Diagnostics (Basel). 2024; 14(16).

PMID: 39202263 PMC: 11354065. DOI: 10.3390/diagnostics14161775.


COVID-19 vaccine registry for pregnant women: policy to control complications of vaccination in pregnant women in 2021-2022.

Asadi F, Shakiba R, Rabiei R, Emami H, Sabahi A BMC Pregnancy Childbirth. 2023; 23(1):542.

PMID: 37501112 PMC: 10375670. DOI: 10.1186/s12884-023-05856-3.


Safety and efficacy of inactivated COVID-19 vaccines in women vaccinated during the first trimester of pregnancy.

Ma Y, Shan Z, Gu Y, Huang Y Int J Infect Dis. 2023; 130:196-202.

PMID: 36924838 PMC: 10014124. DOI: 10.1016/j.ijid.2023.03.017.


Attitudes toward COVID-19 vaccination during the state of emergency in Osaka, Japan.

Odani S, Koyama S, Katsumi Y, Miyashiro I PLoS One. 2022; 17(12):e0279481.

PMID: 36584068 PMC: 9803118. DOI: 10.1371/journal.pone.0279481.


References
1.
Zhou J, Wang W, Zhong Q, Hou W, Yang Z, Xiao S . Immunogenicity, safety, and protective efficacy of an inactivated SARS-associated coronavirus vaccine in rhesus monkeys. Vaccine. 2005; 23(24):3202-9. PMC: 7115379. DOI: 10.1016/j.vaccine.2004.11.075. View

2.
Hayakawa S, Komine-Aizawa S, Mor G . Covid-19 pandemic and pregnancy. J Obstet Gynaecol Res. 2020; 46(10):1958-1966. PMC: 7436660. DOI: 10.1111/jog.14384. View

3.
Chagla Z . The BNT162b2 (BioNTech/Pfizer) vaccine had 95% efficacy against COVID-19 ≥7 days after the 2nd dose. Ann Intern Med. 2021; 174(2):JC15. DOI: 10.7326/ACPJ202102160-015. View

4.
Takano T, Yamada S, Doki T, Hohdatsu T . Pathogenesis of oral type I feline infectious peritonitis virus (FIPV) infection: Antibody-dependent enhancement infection of cats with type I FIPV via the oral route. J Vet Med Sci. 2019; 81(6):911-915. PMC: 6612493. DOI: 10.1292/jvms.18-0702. View

5.
Pardi N, Hogan M, Porter F, Weissman D . mRNA vaccines - a new era in vaccinology. Nat Rev Drug Discov. 2018; 17(4):261-279. PMC: 5906799. DOI: 10.1038/nrd.2017.243. View